Global Public Health 3.0 needs to be understood and adopted.

Until we all look beyond vertical disease-specific programming, funding will be inadequate and responses will be patchy. Public health groups are all submitting recommendations and requests to the incoming Administration. There is the HIV/AIDS pandemic, the growing TB problem, the Malaria situation to name just a few that are the focus of the article below.

David. S. Battisti1 and Rosamond L. Naylor2
1 Department of Atmospheric Sciences, University of Washington, USA.
2 Program on Food Security and the Environment, Stanford University, USA

Science 9 January 2009:
Vol. 323. no. 5911, pp. 240 – 244 DOI: 10.1126/science.1164363

Available online at: http://www.sciencemag.org/cgi/content/full/323/5911/240

http://freakonomics.blogs.nytimes.com/2009/01/07/green-technology-plans-...

A Freakonomics Quorum: How Will the Recession Affect Clean Technology?
By STEPHEN J. DUBNER

Way back when in 2006, here’s what venture-capital legend John Doerr
had to say about clean technology: “This field of greentech could be
the largest economic opportunity of the 21st century.”

As recently as early 2008, plenty of investors and technology
companies were still predicting a clean-tech boom.

But now? With a recession that has scrambled nearly everyone’s

MIT Computer Program Analyzes Environmental Changes, Could
Aid Malaria Prevention Efforts, Researchers Say

Access this story and related links online:
http://www.kaisernetwork.org/daily_reports/rep_index.cfm?DR_ID=56260

A computer program developed at the Massachusetts Institute of
Technology could help in malaria prevention efforts by
identifying which environmental changes would be most effective
in controlling the spread of mosquito-borne diseases, VOA News
reports. The program -- based on four years of research in a
mosquito-endemic area of Niger -- compares conventional

New York Times January 9, 2009

Major Flu Strain Found Resistant to Leading Drug, Puzzling Scientists
By DONALD G. McNEIL Jr.

Virtually all the dominant strain of flu in the United States this season is resistant to the leading antiviral drug Tamiflu, and scientists and health officials are trying to figure out why.

The problem is not yet a public health crisis because this has been a below-average flu season so far, and because the Tamiflu-resistant strain, one of three circulating, is still susceptible to other drugs. But infectious disease specialists are worried nonetheless.